ReviewInfectious agents and cancer2025
Prophylactic vaccines against HPV-caused cervical cancer: novel vaccines are still demanded.
Review in Infectious agents and cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The effectiveness of gender-neutral HPV vaccination programmes in preventing HPV-associated oral cancers: a systematic review.BMC cancer · 2026Pooled it
- Beyond Vaccine Efficacy: Redefining the Next Era of Human Papillomavirus Vaccination.Vaccines · 2026Article
- Computational structural dynamics and immunoinformatic analysis of EIEC IpaHMolecular diversity · 2026Article
- Diverse non-vaccine high-risk HPV genotypes in rural Kerala: implications for cervical cancer prevention in an underserved population.Infectious agents and cancer · 2026Article
- Article
- In Silico Design and Subsequent Expression of Human Papillomavirus-16 and -18 L1 Vaccine Antigens in Broccoli.Vaccines · 2026Article
- Virus Biomimetic-Delivery Systems for the Production of Vaccines.Biomimetics (Basel, Switzerland) · 2026Review
- Article
- Design and computational evaluation of a prophylactic and therapeutic multi-epitope vaccine candidate against cervical cancer.Virology journal · 2026Article
- Cervical Cancer Screening in Transition: Global Challenges and Local Realities.International journal of women's health · 2026Review
- Systems Vaccinology-Integrated Proteomics to Develop a Novel Prophylactic and Therapeutic Vaccine Against Human Papillomavirus 16.Bioinformatics and biology insights · 2026Article
- The immune microenvironment of pathogen-associated cancers and current clinical therapeutics.Molecular cancer · 2025Review
- Epidemiological characteristics and genotype distribution of human papillomavirus infection in Yangpu district, Shanghai, 2020-2024.Virology journal · 2025Article
- Cell-Free Expression of HPV16 Minor Capsid Protein L2 and Its Interaction with S100A10.Protein and peptide letters · 2025Article
- The vaginal microbiome in HPV persistence and cervical cancer progression.Frontiers in cellular and infection microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several high-risk types of human papillomaviruses (HPVs) are associated with cervical cancer and other malignancies. Despite the tremendous success of marketed prophylactic HPV vaccines for the past 18 years, cervical cancer remains a significant global challenge. A nearly 10% increase in new cervical cancer cases worldwide from 2020 to 2022 underscores the urgent need for enhanced vaccination efforts. Current HPV vaccines, including Cervarix®, Gardasil®, Gardasil®9, Cecolin®, and Walrinvax® utilize VLP (virus-like particle) structures and have demonstrated significant efficacy. However, challenges such as type-limited coverage, cold-chain requirements, and affordability emphasize the critical need for further research and development of novel HPV vaccines. Some investigational vaccines, for instance, those using VLPs to carry protective antigens with broader coverage across different viral types, show promise for the future of cervical cancer prevention. Realizing this hope and making further progress still depend on the dedication and innovation of the scientists and authorities involved. This review focuses on both approved and investigational preventive vaccines, including also those designed for simultaneous prevention and therapy. Clinical trials are briefly reviewed, and potential strategies to advance vaccination against HPV-induced cervical cancer are summarized. This review emphasizes approaches that require further investigation in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.